Novavax Stock Total Debt

NVAX Stock

USD 8.72 0.10 1.16%

Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.

Cash Accounts Payable

Total Debt To Capitalization is likely to drop to -0.32 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novavax Company Total Debt Analysis

Novavax's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Novavax Total Debt

229.08 M

Most of Novavax's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novavax Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Novavax is extremely important. It helps to project a fair market value of Novavax Stock properly, considering its historical fundamentals such as Total Debt. Since Novavax's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novavax's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novavax's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Intangible Assets	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.55	-0.89	-0.91	0.93	0.96	0.99	0.88	-0.46	0.63	-0.37	0.33	-0.98	0.87	0.77	0.96	-0.19	-0.62	0.47	0.94	-0.21	0.67	-0.41	-0.61	-0.78
Total Stockholder Equity	-0.55		0.42	0.79	-0.72	-0.76	-0.48	-0.4	0.35	0.0	0.15	-0.19	0.67	-0.74	-0.3	-0.46	0.71	0.99	-0.27	-0.68	0.13	-0.59	0.92	0.93	0.45
Net Debt	-0.89	0.42		0.69	-0.83	-0.83	-0.91	-0.76	0.23	-0.57	0.46	-0.03	0.87	-0.66	-0.85	-0.76	0.23	0.5	-0.18	-0.72	-0.02	-0.35	0.34	0.58	0.58
Retained Earnings	-0.91	0.79	0.69		-0.93	-0.97	-0.85	-0.77	0.5	-0.41	0.28	-0.33	0.95	-0.97	-0.54	-0.89	0.38	0.83	-0.52	-0.98	0.25	-0.79	0.68	0.78	0.77
Accounts Payable	0.93	-0.72	-0.83	-0.93		0.96	0.89	0.68	-0.41	0.6	-0.36	0.17	-0.96	0.93	0.57	0.87	-0.32	-0.77	0.39	0.91	-0.16	0.63	-0.59	-0.82	-0.71
Total Liab	0.96	-0.76	-0.83	-0.97	0.96		0.93	0.82	-0.47	0.49	-0.34	0.32	-0.98	0.93	0.69	0.9	-0.38	-0.81	0.46	0.96	-0.21	0.72	-0.63	-0.78	-0.76
Total Current Assets	0.99	-0.48	-0.91	-0.85	0.89	0.93		0.87	-0.45	0.67	-0.38	0.36	-0.95	0.8	0.83	0.93	-0.16	-0.57	0.47	0.89	-0.21	0.63	-0.32	-0.54	-0.76
Net Receivables	0.88	-0.4	-0.76	-0.77	0.68	0.82	0.87		-0.38	0.35	-0.43	0.31	-0.85	0.74	0.78	0.87	-0.15	-0.45	0.34	0.85	-0.14	0.6	-0.34	-0.36	-0.72
Intangible Assets	-0.46	0.35	0.23	0.5	-0.41	-0.47	-0.45	-0.38		-0.29	0.08	-0.53	0.44	-0.43	-0.29	-0.52	-0.12	0.36	-0.64	-0.53	0.53	-0.59	0.22	0.28	0.49
Short Term Debt	0.63	0.0	-0.57	-0.41	0.6	0.49	0.67	0.35	-0.29		-0.32	0.37	-0.55	0.41	0.42	0.63	0.17	-0.12	0.34	0.48	-0.14	0.42	0.28	-0.12	-0.56
Common Stock	-0.37	0.15	0.46	0.28	-0.36	-0.34	-0.38	-0.43	0.08	-0.32		0.09	0.43	-0.3	-0.33	-0.34	0.22	0.2	0.25	-0.32	-0.27	-0.14	0.05	0.17	0.63
Long Term Debt	0.33	-0.19	-0.03	-0.33	0.17	0.32	0.36	0.31	-0.53	0.37	0.09		-0.24	0.15	0.37	0.36	-0.08	-0.25	0.67	0.35	-0.47	0.68	0.11	0.03	-0.48
Treasury Stock	-0.98	0.67	0.87	0.95	-0.96	-0.98	-0.95	-0.85	0.44	-0.55	0.43	-0.24		-0.93	-0.7	-0.93	0.31	0.73	-0.39	-0.96	0.15	-0.67	0.54	0.72	0.77
Property Plant Equipment	0.87	-0.74	-0.66	-0.97	0.93	0.93	0.8	0.74	-0.43	0.41	-0.3	0.15	-0.93		0.41	0.89	-0.28	-0.75	0.4	0.96	-0.18	0.68	-0.67	-0.76	-0.69
Current Deferred Revenue	0.77	-0.3	-0.85	-0.54	0.57	0.69	0.83	0.78	-0.29	0.42	-0.33	0.37	-0.7	0.41		0.63	-0.23	-0.4	0.31	0.58	-0.12	0.41	-0.17	-0.33	-0.54
Good Will	0.96	-0.46	-0.76	-0.89	0.87	0.9	0.93	0.87	-0.52	0.63	-0.34	0.36	-0.93	0.89	0.63		-0.08	-0.52	0.51	0.96	-0.21	0.73	-0.33	-0.49	-0.81
Short Term Investments	-0.19	0.71	0.23	0.38	-0.32	-0.38	-0.16	-0.15	-0.12	0.17	0.22	-0.08	0.31	-0.28	-0.23	-0.08		0.73	0.25	-0.25	-0.42	-0.34	0.62	0.6	0.25
Net Tangible Assets	-0.62	0.99	0.5	0.83	-0.77	-0.81	-0.57	-0.45	0.36	-0.12	0.2	-0.25	0.73	-0.75	-0.4	-0.52	0.73		-0.29	-0.72	0.11	-0.65	0.86	0.93	0.53
Long Term Debt Total	0.47	-0.27	-0.18	-0.52	0.39	0.46	0.47	0.34	-0.64	0.34	0.25	0.67	-0.39	0.4	0.31	0.51	0.25	-0.29		0.53	-0.82	0.62	-0.15	-0.23	-0.47
Capital Surpluse	0.94	-0.68	-0.72	-0.98	0.91	0.96	0.89	0.85	-0.53	0.48	-0.32	0.35	-0.96	0.96	0.58	0.96	-0.25	-0.72	0.53		-0.26	0.79	-0.57	-0.67	-0.81
Deferred Long Term Liab	-0.21	0.13	-0.02	0.25	-0.16	-0.21	-0.21	-0.14	0.53	-0.14	-0.27	-0.47	0.15	-0.18	-0.12	-0.21	-0.42	0.11	-0.82	-0.26		-0.33	0.07	0.09	0.17
Short Long Term Debt	0.67	-0.59	-0.35	-0.79	0.63	0.72	0.63	0.6	-0.59	0.42	-0.14	0.68	-0.67	0.68	0.41	0.73	-0.34	-0.65	0.62	0.79	-0.33		-0.36	-0.43	-0.77
Net Invested Capital	-0.41	0.92	0.34	0.68	-0.59	-0.63	-0.32	-0.34	0.22	0.28	0.05	0.11	0.54	-0.67	-0.17	-0.33	0.62	0.86	-0.15	-0.57	0.07	-0.36		0.9	0.26
Net Working Capital	-0.61	0.93	0.58	0.78	-0.82	-0.78	-0.54	-0.36	0.28	-0.12	0.17	0.03	0.72	-0.76	-0.33	-0.49	0.6	0.93	-0.23	-0.67	0.09	-0.43	0.9		0.41
Capital Stock	-0.78	0.45	0.58	0.77	-0.71	-0.76	-0.76	-0.72	0.49	-0.56	0.63	-0.48	0.77	-0.69	-0.54	-0.81	0.25	0.53	-0.47	-0.81	0.17	-0.77	0.26	0.41

Click cells to compare fundamentals

Novavax Total Debt Historical Pattern

Today, most investors in Novavax Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novavax's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novavax total debt as a starting point in their analysis.

Novavax Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Novavax

Short Long Term Debt Total Over Time

Novavax Net Debt

Net Debt

(322.45 Million)

Novavax reported Net Debt of (339.42 Million) in 2023

Based on the latest financial disclosure, Novavax has a Total Debt of 229.08 M. This is 91.67% lower than that of the Biotechnology sector and 29.47% lower than that of the Health Care industry. The total debt for all United States stocks is 95.69% higher than that of the company.

Novavax Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.

Novavax is currently under evaluation in total debt category among its peers.

Novavax ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novavax's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novavax's managers, analysts, and investors.

Environmental

Governance

Social

Novavax Institutional Holders

Institutional Holdings refers to the ownership stake in Novavax that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novavax's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novavax's value.

		Shares
Jane Street Group Llc	2024-06-30	1.9 M
Goldman Sachs Group Inc	2024-06-30	1.4 M
Northern Trust Corp	2024-09-30	1.4 M
Tsp Capital Management Group/llc	2024-09-30	1.4 M
Two Sigma Advisers, Llc	2024-06-30	1.3 M
Charles Schwab Investment Management Inc	2024-09-30	1.3 M
Sg Americas Securities, Llc	2024-09-30	1.2 M
Citigroup Inc	2024-09-30	1.1 M
Tang Capital Management Llc	2024-09-30	1000 K
Vanguard Group Inc	2024-09-30	15.4 M
Blackrock Inc	2024-06-30	11.8 M

Novavax Fundamentals

	Return On Equity	-8.98
	Return On Asset	-0.11
	Profit Margin	(0.32) %
	Operating Margin	(1.54) %
	Current Valuation	720.59 M
	Shares Outstanding	160.18 M
	Shares Owned By Insiders	4.37 %
	Shares Owned By Institutions	60.11 %
	Number Of Shares Shorted	41.51 M
	Price To Earning	(1.36) X
	Price To Book	49.52 X
	Price To Sales	1.58 X
	Revenue	983.71 M
	Gross Profit	(156.04 M)
	EBITDA	(487.39 M)
	Net Income	(545.06 M)
	Cash And Equivalents	1.28 B
	Cash Per Share	16.31 X
	Total Debt	229.08 M
	Debt To Equity	8.24 %
	Current Ratio	1.05 X
	Book Value Per Share	(3.29) X
	Cash Flow From Operations	(713.97 M)
	Short Ratio	5.97 X
	Earnings Per Share	(2.18) X
	Target Price	16.0
	Number Of Employees	1.54 K
	Beta	2.09
	Market Capitalization	1.4 B
	Total Asset	1.8 B
	Retained Earnings	(4.82 B)
	Working Capital	(491.25 M)
	Current Asset	287.26 M
	Current Liabilities	76.49 M
	Net Asset	1.8 B

About Novavax Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC